Management Team

Robert G. McNeil


Robert McNeil has over 35 years of experience as an active investor and management participant in seed and early-stage life science companies. He founded Sanderling Ventures in 1979 and has served since then as managing director of Sanderling’s seven investment partnerships. Previously, Dr. McNeil was the seed investor for several companies that became the corner stones in the practice of modern medicine, including Advanced Cardiovascular Systems (the basis of Guidant Corp.) and Ventritex (the basis of rhythm management at St. Jude Medical). His ability to develop a close relationship with management and careful understanding of the companies’ technologies has allowed successful development of products at very early stage. Dr. McNeil earned his doctorate in the fields of molecular biology, biochemistry and genetics from the University of California, Irvine.

Fred Hochberg, MD


Fred Hochberg, MD, is an authority on Exosome-based ‘liquid biopsies’ for cancer diagnosis. As Attending Neurologist, Massachusetts General Hospital he was responsible for Phase I and Phase II studies including the current curative use of high dose methotrexate to cure Central Nervous System Lymphoma and pro-drug activating Herpes Viral vectors to treat malignant brain tumors. His work provided the foundation for localized irradiation of these tumors. As a founding member of the NCI UO1 Phase I ‘New Approaches to Brain Tumor Therapy’ and the Neuro-Oncology Program at Harvard Medical School hospitals, he performed the studies linking lymphoma to viral infection, developed high dose chemotherapy with autologous bone marrow transplantation for brain tumors, studied modifiers of the blood-brain barrier and administration of Alkylating chemotherapy by arterial infusion. He authored over 200 peer reviewed manuscripts,  and has had continuous National Institutes of Health (NIH) program support for over 30 years, including 18 years as the principal investigator of gene therapy and exosome-based projects. He has been a founding Board Member of the International Society for Extracellular Vesicles. Currently Dr. Hochberg is a visiting professor at the Scintillon Institute (LaJolla) and recently Visiting Professor of Neurosurgery at the University of California at San Diego.

Stephen J. Gould


Stephen J. Gould is Professor of Biological Chemistry at Johns Hopkins University, Co-director of the Johns Hopkins University Graduate Program in Biological Chemistry, and co-Founder and President of the American Society for Exosomes and Microvesicles (ASEMV). Dr. Gould’s research interests lie at the intersection of cell biology and human disease, and his work on exosomes has led to major insights into how and why cells make these small, secreted vesicles, how exosomes can serve as a platform for selectively delivery of anti-neoplastic & anti-fibrotic agents to tumors and sites of tissue damage, and was the first to propose exosome biogenesis as the mechanism of virus production in HIV/AIDS and other viral infections. Dr. Gould has published more than 100 research articles, numerous invited reviews, several book chapters. Dr. Gould has also served on dozens of NIH and other grant review panels, has reviewed scores of research articles, organized numerous scientific conferences, and has been awarded millions of dollars in federal and other grants to support his research activities. Dr. Gould teaches metabolism and exercise metabolism to 1st year and 3rd year medical students, and developed the first graduate class on exosome biology, which he teaches to Ph.D. students at Johns Hopkins University. Dr. Gould earned his doctorate at the University of California, San Diego (Biology) after receiving his bachelor’s degree from the University of California, Santa Barbara (Aquatic Biology).

Michael Dixon


Michael Dixon, CPA CA has over 18 years of experience working in an executive role for venture-backed companies. As CEO of Therillia Development Company Inc., Mr. Dixon oversees the development of therapeutic assets of interest to Therillia’s shareholders, including dalcetrapib. Prior to his role in Therillia, Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada. Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.